DDX41 mutations in patients with non‐myeloid hematologic neoplasms
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26952 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Fatima Zahra Jelloul und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
The role of DDX41 mutations in the development of myeloid neoplasms (MN) is becoming well established.1-3 Germline mutations in DDX41 have been shown to predispose to additional somatic DDX41 mutations and confer an increased risk of developing MN, including acute myeloid leukemia and myelodysplastic syndromes. MN with germline DDX41 mutations have many unique clinical and pathologic features and have thus been recognized as a distinct entity in the current World Health Organization classification. Earlier studies, including one from our department, have reported the clinical, pathologic, and molecular characteristics of MN associated with DDX41 mutation.4 DDX41 mutations were also identified rarely in non-myeloid hematologic neoplasms in previous studies, although very little information is available in this regard and the extent to which these DDX41 mutations are contributing to non-myeloid malignancies, particularly non-myeloid hematologic malignancies, has yet to be fully determined. The purpose of this study was to further address this question as well as the prevalence and characteristics of DDX41 mutations in non-myeloid hematologic malignancies. We reviewed our database for all malignancies with a DDX41 mutation detected by our Endleukemia assay V2, an 81-gene clinical next-generation sequencing (NGS) assay performed on all new or suspected acute leukemias or MN. After excluding patients with an established history of MN, we identified a cohort of 20 patients. Clinical, cytogenetic and molecular characteristics were collected. Statistical analysis was performed using GraphPad Prism (GraphPad software, San Diego, CA, USA) with significance set at a p-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Fatima Zahra Jelloul, Courtney D DiNardo, Rashmi Kanagal-Shamanna, Beenu Thakral, C Cameron Yin, Sanam Loghavi, Chi Young Ok, Sa A Wang, Zhenya Tang, M James You, Andrés E Quesada
Zitieren
APA
Jelloul, F. Z., Routbort, M. J., DiNardo, C. D., Bueso-Ramos, C. E., Kanagal-Shamanna, R., Thakral, B., Zuo, Z., Yin, C. C., Loghavi, S., Ok, C. Y., Wang, S. A., Tang, Z., You, M. J., Patel, K. P., Medeiros, L. J., & Quesada, A. E. (2023). DDX41 mutations in patients with non‐myeloid hematologic neoplasms. American Journal of Hematology. https://doi.org/10.1002/ajh.26952
Vancouver
Jelloul FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, et al. DDX41 mutations in patients with non‐myeloid hematologic neoplasms. American Journal of Hematology. 2023. doi:10.1002/ajh.26952
BibTeX
@article{Jelloul2023,
author = {Jelloul, Fatima Zahra and Routbort, Mark J and DiNardo, Courtney D and Bueso-Ramos, Carlos E and Kanagal-Shamanna, Rashmi and Thakral, Beenu and Zuo, Zhuang and Yin, C Cameron and Loghavi, Sanam and Ok, Chi Young and Wang, Sa A and Tang, Zhenya and You, M James and Patel, Keyur P and Medeiros, L Jeffrey and Quesada, Andrés E},
title = {DDX41 mutations in patients with non‐myeloid hematologic neoplasms},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26952}
}
EUVIMED